Streetbeat News

NPCE

NeuroPace, Inc.

https://www.neuropace.com

Industry

Medical - Devices

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Open

10.69

Mkt cap

348M

Volume

97K

High

10.82

P/E Ratio

-11.49

52-wk high

15.78

Low

10.52

Div yield

N/A

52-wk low

5.45

NeuroPace (NPCE) experienced a 5.8% surge in its stock price with higher than average trading volume. However, recent trends in earnings estimate revisions suggest that this may not lead to further price increases in the near term.

Portfolio Pulse from

February 21, 2025 | 11:30 am

NeuroPace, Inc. has completed the repurchase of 5.3 million shares from KCK Ltd., using funds from a recent public offering. This move strengthens its balance sheet and supports operations until cash flow breakeven. The company also terminated its ATM offering program.

Portfolio Pulse from

February 20, 2025 | 9:15 pm

NeuroPace, Inc. (Nasdaq: NPCE) will release its Q4 and full-year 2024 financial results on March 4, 2025. The announcement will occur after market close.

Portfolio Pulse from

February 19, 2025 | 9:30 pm

NeuroPace, Inc. has completed its public offering of 7,475,000 shares at $10.00 per share, including the full exercise of the underwriters' option to purchase additional shares.

Portfolio Pulse from

February 18, 2025 | 9:30 pm

NeuroPace, Inc. has announced the pricing of a public offering of 6.5 million shares of its common stock at $10.00 per share, aiming to raise $65 million.

Portfolio Pulse from

February 14, 2025 | 11:45 am

NeuroPace, Inc. (Nasdaq: NPCE) announced a proposed public offering of $65 million in common stock, with an option for underwriters to purchase an additional 15%. The offering's completion is subject to market conditions.

Portfolio Pulse from

February 13, 2025 | 9:45 pm

NeuroPace, Inc. (Nasdaq: NPCE) will present data from its Post-approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting. This presentation could highlight the effectiveness and impact of their epilepsy treatment device.

Portfolio Pulse from

February 03, 2025 | 9:15 pm

NeuroPace, Inc. has issued its 2025 financial guidance, projecting revenues between $92 million and $96 million, with a gross margin of 73% to 75%. The company aims for a 20% revenue CAGR over three years and to achieve cash flow breakeven.

Portfolio Pulse from

January 28, 2025 | 10:30 pm

NeuroPace (NPCE) experienced a 9.1% increase in its stock price with higher than average trading volume. However, recent trends in earnings estimate revisions suggest that further price increases may not be imminent.

Portfolio Pulse from

January 22, 2025 | 12:00 pm

NeuroPace has announced its preliminary unaudited revenue for Q4 2024, expected to be between $21.0 million and $21.5 million, and for the full year 2024, between $79.4 million and $79.9 million.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.